What is Palmitoylethanolamide?
Palmitoylethanolamide is an endogenous (manufactured by the body) fatty acid amide. It has been extensively researched since its discovery in 1957, including by neurobiologist Rita Levi-Montalcini who won a Nobel prize on unrelated work. In a nutshell, Palmitoylethanolamide is a natural molecule, that is (amongst other reasons) produced by the body on demand to reduce pain and inflammation.
Palmitoylethanolamide is a nutraceutical, it is found naturally in foods such as egg yolks, peanuts, meats, and dairy products.
What is the active ingredient in CannAMP known for?
The active ingredient in CannAMP has been shown to have several positive effects, including anti-inflammatory properties, analgesic properties (related to it anti-inflammatory action), neuroprotective properties and regulation of the immune system.
These benefits come from The active ingredient in CannAMP’s effects on several receptors within and beyond the endocannabinoid system.
CannAMP is deemed safe for both short- and long-term use, with virtually no side-effects. It can be taken with other medicines, with no negative interactions reported thus far. So safe with chronic medications. There are also no incidences of allergic reactions reported in the literature and no tolerance build-up, even with long-term moderate use.
Mode of Action
The cells in the body have numerous different receptors on their surfaces. Different molecules can bind to these receptors and their binding trigger biological processes inside the cell. The type of receptor and type of molecule that binds it determines the nature of the process that is triggered.
Most of CannAMP’s benefits come from its actions on six of these cell surface receptors. Its presence can lead to a wide array of benefits for the whole body, including, but not limited to its anti-inflammatory effect.
This is affected by binding directly to some receptors and influencing others through other endogenous molecules, such as anandamide (discussed in the section on CannAMP and the endocannabinoid system).
Research indicates that CannAMP helps to mitigate pain associated with various conditions. The production of CannAMP is part of the way that the body naturally deals with pain and inflammation, producing it at the inflamed site. This increase in CannAMP concentration is what counters inflammation, additionally leading to a reduction in pain.
Unfortunately, several studies have showed that the active ingredient in CannAMP is less present in patients suffering from chronic conditions. This is as the body fails to produce sufficient amounts of the active ingredient in CannAMP as the two enzymes in the body that naturally degrade the active ingredient in CannAMP, do this very quickly.
This is why taking CannAMP beneficial for chronic pain, thereby increasing the amount of the active ingredient in CannAMP in the body and helping it deal with pain naturally and safely. Increasing the amount of the active ingredient in CannAMP in the body by supplementation increases its benefits and prolongs the time over which it can exert its positive effects. This is not only limited to helping alleviate chronic pain from inflammation, but also helps with pain from other sources of inflammation, such as from inflammatory processes related to flu and cold.
Research on CannAMP’s ability to alleviate pain spans several decades and a reduction in pain seen as early as 15 days of consecutive use. Anecdotal evidence, however, suggests that this effect can also be experienced in a couple of hours (i.e. an acute effect).
In addition to its effect on pain and inflammation, CannAMP has shown benefits against other conditions potentially related to increased levels of inflammation, such as stroke, multiple sclerosis, Alzheimer’s disease Parkinson’s disease and depression and anxiety. Furthermore, CannAMP can also improve immunity, makes it effective against numerous diseases which come from an immune system imbalance. This is especially important for people who suffer from numerous autoimmune and autoinflammatory diseases.
One of the ingredients in CannAMP is soy lecithin, which is extracted from soybeans. Soy lecithin has traditionally been used as a herbal medicinal product for the relief of temporary fatigue and sensation of weakness. Additionally, research has shown that daily administration of soy lecithin may be used as a supplemental treatment for high cholesterol and can even improve other aspects of cardiovascular health, beyond the lowering of cholesterol.
Why is CannAMP produced as a liposome?
While the active ingredient in CannAMP has great benefits, also some challenges. The main half-life is very short as it gets degraded by enzymes and digestive fluids before it reaches the cells that need it.
The solution? Create a liposome using the active ingredient in CannAMP.
This protects CannAMP from degradation (either by enzymes or digestive fluids) and delivers it to cells where it is needed, enabling its absorption, and thereby increasing bioavailability, thus, a better efficacy that if it were in a non-liposomal form.
Palmitoylethanolamide and the endocannabinoid system
As mentioned earlier, CannAMP also has a relationship with the endocannabinoid anandamide. In fact, it is an analogue of this endocannabinoid. Part of its mode of action is therefore related to the endocannabinoid system, a naturally occurring system that exists in humans, as well as other animals, and plants.
The system has two main cannabinoid receptors, CB1 and CB2. CB1 is most prominent in the central nervous system and also present in the kidneys, liver and lungs where it, amongst other things, deals with pain-related issues. CB2, on the other hand, is involved in the immune system and is found in hematopoietic cells, B cells and macrophages . CB2 is involved in eliminating microbes, cellular debris and cancer cells (done by macrophages), helping create antibodies (by B cells) and increasing the number of blood cell (by hematopoietic cells).
While it does play a role in this system, CannAMP itself lacks a strong affinity for cannabinoid receptors CB1 and CB2. It is therefore not classified as an endocannabinoid, but rather its presence in the system increases cannabinoid receptor activity through something known as the “entourage effect” (synergy), increasing the sensitivity of the cannabinoid receptors to endocannabinoids, as well as exogenous (external) cannabinoids. Taking CannAMP while ingesting cannabinoids could therefore lead to an enhancement of their effects and an increase in the duration thereof, implying that a reduced dosage of the cannabinoid (such as cannabidiol) could be used to reach the same effect. So therefore, less cost and reduced side effects for potentially the same therapeutic effect of a higher dose of cannabinoid.
This is suspected to occur because of CannAMP’s relationship to anandamide. This endocannabinoid plays a major role in the body and is also quickly and easily degraded by the same enzyme that degrades CannAMP. This means that having more CannAMP in the body increases the efficacy of both anandamide and CannAMP and the enzyme cannot degrade both as quickly as it would usually, meaning both can provide the body with their benefits for longer and explaining CannAMP’s positive effect on the endocannabinoid system.
In the absence of (external) cannabinoids, CannAMP would act as it does within your body and perform its natural functions.